Doctronic Closes $40M Series B Funding Round
AI doctor startup Doctronic has raised $40 million in a Series B funding round, bringing its total capital raised to $65 million. Notably, this marks the company’s third funding round in under a year. The New York-based startup offers a free, HIPAA-compliant, AI-powered doctor consultation platform that operates 24/7 and autonomously makes clinical decisions.
Doctronic launched in 2023 and first introduced services with human clinicians in January 2025. Since then, the platform has grown rapidly. It now serves more than 300,000 unique weekly visitors and has conducted over 15 million medical conversations with more than one million users.
Who Led the Investment?
Investors and Participation
The Series B round was co-led by Abstract and Lightspeed Venture Partners. Existing investors — Seven Stars, Union Square Ventures, Tusk Ventures, and Mantis — also participated. Lightspeed previously led Doctronic’s Series A round and chose to double down on this latest raise.
Prior to the Series B, Doctronic secured $20 million in its Series A and an additional $5 million from Union Square Ventures. Together, these rounds bring total funding to $65 million.
What Makes Doctronic Different?
A Platform Built for Clinical Responsibility
Unlike general-purpose AI health tools, Doctronic takes direct responsibility for clinical outcomes. The platform runs on a collective intelligence architecture. Multiple specialized AI agents conduct structured clinical reasoning under physician oversight. Each patient interaction also feeds a proprietary dataset, which continuously improves diagnostic precision over time.
The system responds to medical questions with detailed explanations and follows up with clinical questions to guide assessments. Furthermore, when a case requires medication, lab work, or physician judgment, the platform connects users to board-certified doctors via video consultations — available around the clock for a standard insurance copay or a flat $39 fee without insurance.
Safety Protocols and Clinical Performance
Doctronic’s AI performs dozens of safety checks per prescription renewal. According to co-founder Dr. Adam Oskowitz, those same checks would take a human physician roughly an hour. The platform reports a 99.2% treatment alignment rate based on real patient data. Additionally, all cases involving complexity trigger automatic escalation to licensed physicians at any hour.
The Utah Prescription Milestone
First AI to Legally Prescribe in the U.S.
In December 2025, Doctronic crossed a landmark threshold in American healthcare. The company became the first AI-native platform to autonomously renew prescriptions under Utah’s AI Learning Lab regulatory sandbox. Through a formal agreement with Utah’s Department of Commerce Office of Artificial Intelligence Policy, patients with chronic conditions began receiving medication refills directly through AI — without requiring a physician intermediary.
The program currently covers 190 medications and runs under strict safety and reporting protocols. Doctronic is now in discussions with regulators in other states, as well as international governments, to expand its prescription services beyond Utah.
Federal Legislation on the Horizon
The Healthy Technology Act of 2025
At the federal level, proposed legislation adds further momentum to Doctronic’s mission. Representative David Schweikert of Arizona introduced the “Healthy Technology Act of 2025,” which would formally recognize AI as a practitioner licensed to prescribe FDA-approved drugs. If enacted, the bill would fundamentally reshape the regulatory landscape for AI healthcare platforms across the country. The bill currently sits with the House Committee on Energy and Commerce.
Where the Funding Goes Next
Expansion Plans Across Verticals
Doctronic plans to deploy the fresh capital across several strategic fronts. First, the company will accelerate hiring to keep pace with its rapid growth. Second, it will expand into pediatrics, an area where consumer demand far outpaces current access to care. Third, it will build new partnerships with hospital systems, academic medical centers, digital health platforms, and payers.
How Health Systems and Payers View Doctronic
Health systems view the platform as digital front-door infrastructure that routes patients efficiently and keeps care in-network. Payers, meanwhile, see it as a solution for delivering unlimited primary care at a predictable cost. Co-CEO Matt Pavelle described the round as a reflection of the company’s category leadership and its ability to serve millions of consumers directly.
Growth Metrics Behind the Raise
Revenue and Retention Data
Since closing its Series A in September 2025, Doctronic has achieved 15x revenue growth, reaching 8-figure annualized revenue. The company also nearly tripled its repeat patient rate during this period. These metrics signal genuine product-market fit at an early stage — a combination rarely seen in consumer health at this scale.
The platform is on track to earn more than $10 million in revenue this year. It also plans to roll out co-branded versions of its technology with partners across digital health, health systems, and payer organizations.
